Verbatim response from ChatGPT
Short version
- The FDA has cracked down on pharmacies and clinics that were compounding GLP‑1 peptides (like semaglutide and tirzepatide) from bulk active pharmaceutical ingredients (APIs) and shipping them widely without valid, patient‑specific prescriptions. The agency says that when safe, approved products are available, compounding from bulk substances or foreign APIs is unlawful and potentially unsafe.
- That action has included public safety alerts and warning letters to compounding operations. The result: many online sellers of “cheap” compounded semaglutide or tirzepatide have been told to stop or have been removed from market.
Why the FDA acted (brief)
- GLP‑1 drugs such as Wegovy, Ozempic, Rybelsus (semaglutide) and Mounjaro, Zepbound (tirzepatide) are FDA‑approved for diabetes and/or chronic weight management. The FDA’s position: compounding from bulk drug substances is limited and generally not allowed when an FDA‑approved product exists. There are also safety concerns about APIs sourced from unregulated foreign suppliers and about sterility/labeling/quality when products are mass‑distributed rather than made for an individual patient.
Who can legally provide GLP‑1 therapy now
- Licensed prescribers (primary care doctors, endocrinologists, obesity medicine specialists) prescribing FDA‑approved products. Getting Wegovy, Ozempic, Rybelsus, Mounjaro or Zepbound by prescription from a licensed clinician is legal and recommended because manufacturers’ products meet FDA quality standards.
- Traditional 503A compounding pharmacies may legally compound a medication only if there is a valid, patient‑specific prescription and they follow state and federal rules (and typically they should not compound from bulk APIs that are not permitted). Patient‑specific compounding—done for one named patient, under a prescriber’s order—can be lawful.
- 503B outsourcing facilities (FDA‑registered) may compound without patient‑specific prescriptions only if the bulk drug substance is on the FDA’s approved 503B Bulks List. As of my last update, semaglutide and tirzepatide were not listed for mass compounding, so most 503B compounding of those GLP‑1s from bulk was not authorized.
Who likely is NOT operating legally
- Online companies or out‑of‑state pharmacies mass‑producing compounded GLP‑1 injections from bulk APIs (especially foreign sources) and shipping them nationwide without patient‑specific prescriptions — these were the primary targets of FDA warnings.
How to protect yourself / practical steps
- Use FDA‑approved products when possible (brands: Wegovy, Ozempic, Rybelsus, Mounjaro, Zepbound) obtained via a licensed clinician and a legitimate pharmacy.
- If a prescriber or clinic offers a compounded GLP‑1, ask:
- Is this being made for you specifically (patient‑specific prescription)?
- Where is the API coming from and can they provide quality/sterility testing results?
- Is the pharmacy licensed in your state (503A) or registered with FDA as a 503B outsourcing facility? (503B facilities must appear on FDA lists.)
- Check the FDA Warning Letters database and your state board of pharmacy for any notices about the pharmacy or clinic.
- If cost/access is the issue, talk with your clinician about manufacturer savings programs, patient assistance, or alternatives rather than buying unverified compounded products online.
Recommended, safer sources (by name and why)
- Wegovy (Novo Nordisk) — FDA‑approved for chronic weight management; manufactured to FDA standards.
- Ozempic (Novo Nordisk) or Rybelsus (oral semaglutide) — approved for type 2 diabetes (Ozempic commonly used off‑label for weight loss under supervision).
- Mounjaro (Eli Lilly) and Zepbound (Eli Lilly) — tirzepatide products with FDA approvals for diabetes (Mounjaro) and, in 2023, for weight management (Zepbound); again, manufactured to FDA standards.
- Your primary care doctor, endocrinologist, obesity/weight‑management clinic, or a licensed telemedicine provider that prescribes these FDA‑approved drugs after an evaluation — these are the safe/legal routes.
If you want, I can:
- Help you check whether a particular pharmacy or online seller has an FDA warning letter or state pharmacy action (tell me the name), or
- Suggest how to talk with your clinician about getting an FDA‑approved GLP‑1 affordably.